Product Description
The In Vitro Diagnostics or IVD market revenue was xx Million USD in 2019, grew to xx Million USD in 2023, and will reach xx Million USD in 2031, with a CAGR of xx during 2024-2031.
Considering the influence of COVID-19 on the global In Vitro Diagnostics or IVD market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Japan, the report put emphasis on analysis of market under COVID-19 and corresponding response policy in different regions.
This report also analyzes the strategies for different companies to deal with the impact of COVID-19 in detail to seek a path to recovery.
Under COVID-19 Outbreak, how the In Vitro Diagnostics or IVD Industry will develop is also analyzed in detail in Chapter 1.8 of this report.
Major Players in In Vitro Diagnostics or IVD market are:
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
Ortho-Clinical Diagnostics, Inc.
Diasorin S.P.A.
Becton, Dickinson and Company
Roche Diagnostics
Siemens AG
Qiagen N.V.
Sysmex Corporation
Danaher Corporation
Abbott Laboratories, Inc.
Johnson & Johnson
Biomérieux SA
Most important types of In Vitro Diagnostics or IVD products covered in this report are:
Immunochemistry/Immunoassays
Clinical Chemistry
Molecular Diagnostics (MDX)
Clinical Microbiology
Hematology
Most widely used downstream fields of In Vitro Diagnostics or IVD market covered in this report are:
Diabetes
Oncology
Cardiology
Nephrology
Infectious Diseases
Major Regions or countries covered in this report:
North America
Europe
China
Japan
Middle East and Africa
South America
India
South Korea
Southeast Asia
Others
In Chapter 3.4, the report provides analysis of the reasons behind price fluctuations.
In chapters 5, 6, and 7, the impact of COVID-19 on the different regions in both production and consumption end and SWOT analysis are pointed out.
In Chapters 8, the report presents company's recent development and strategies to deal with the impact of COVID-19.
